Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.

Ryckbosch SM, Wender PA, Pande VS.

Nat Commun. 2017 Feb 23;8(1):6. doi: 10.1038/s41467-016-0015-8.

2.

Structural insights into the interactions of phorbol ester and bryostatin complexed with protein kinase C: a comparative molecular dynamics simulation study.

Thangsunan P, Tateing S, Hannongbua S, Suree N.

J Biomol Struct Dyn. 2016 Jul;34(7):1561-75. doi: 10.1080/07391102.2015.1084479. Epub 2015 Sep 23.

PMID:
26292580
3.

Modeling studies on the structural determinants for the DAG/phorbol ester binding to C1 domain.

Rahman GM, Das J.

J Biomol Struct Dyn. 2015;33(1):219-32. doi: 10.1080/07391102.2014.895679. Epub 2014 Mar 25.

PMID:
24666138
4.

The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.

Ruan BF, Zhu HL.

Curr Med Chem. 2012;19(16):2652-64. Review.

PMID:
22506770
5.

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.

DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA.

Nat Chem. 2012 Sep;4(9):705-10. doi: 10.1038/nchem.1395. Epub 2012 Jul 15.

6.

Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.

Kedei N, Telek A, Michalowski AM, Kraft MB, Li W, Poudel YB, Rudra A, Petersen ME, Keck GE, Blumberg PM.

Biochem Pharmacol. 2013 Feb 1;85(3):313-24. doi: 10.1016/j.bcp.2012.10.028. Epub 2012 Nov 9.

7.

Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.

Keck GE, Poudel YB, Welch DS, Kraft MB, Truong AP, Stephens JC, Kedei N, Lewin NE, Blumberg PM.

Org Lett. 2009 Feb 5;11(3):593-6. doi: 10.1021/ol8027253.

8.

Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.

Loy BA, Lesser AB, Staveness D, Billingsley KL, Cegelski L, Wender PA.

J Am Chem Soc. 2015 Mar 18;137(10):3678-85. doi: 10.1021/jacs.5b00886. Epub 2015 Mar 4.

9.

Ligand structure-activity requirements and phospholipid dependence for the binding of phorbol esters to protein kinase D.

Wang QJ, Fang TW, Yang D, Lewin NE, Van Lint J, Marquez VE, Blumberg PM.

Mol Pharmacol. 2003 Dec;64(6):1342-8.

10.

Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.

Abdelnabi R, Staveness D, Near KE, Wender PA, Delang L, Neyts J, Leyssen P.

Biochem Pharmacol. 2016 Nov 15;120:15-21. doi: 10.1016/j.bcp.2016.09.020. Epub 2016 Sep 21.

11.

Kinetic analysis of the interaction of the C1 domain of protein kinase C with lipid membranes by stopped-flow spectroscopy.

Dries DR, Newton AC.

J Biol Chem. 2008 Mar 21;283(12):7885-93. doi: 10.1074/jbc.M709943200. Epub 2008 Jan 10.

12.

Inhibition of membrane lipid-independent protein kinase Calpha activity by phorbol esters, diacylglycerols, and bryostatin-1.

Slater SJ, Taddeo FJ, Mazurek A, Stagliano BA, Milano SK, Kelly MB, Ho C, Stubbs CD.

J Biol Chem. 1998 Sep 4;273(36):23160-8.

13.

Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.

Wender PA, Nakagawa Y, Near KE, Staveness D.

Org Lett. 2014 Oct 3;16(19):5136-9. doi: 10.1021/ol502491f. Epub 2014 Sep 19.

15.

Protein kinase C. Modeling of the binding site and prediction of binding constants.

Wang S, Milne GW, Nicklaus MC, Marquez VE, Lee J, Blumberg PM.

J Med Chem. 1994 Apr 29;37(9):1326-38. Erratum in: J Med Chem 1994 Dec 9;37(25):4422.

PMID:
8176711
16.

Phorbol esters as probes for the study of protein kinase C function.

Kazanietz MG, Lorenzo PS.

Methods Mol Biol. 2003;233:423-39. No abstract available.

PMID:
12840526
17.

Protein kinase C in cell signaling: strategies for the development of selective inhibitors.

Blumberg PM, Acs G, Acs P, Areces LB, Kazanietz MG, Lewin NE, Szallasi Z.

Agents Actions Suppl. 1995;47:87-100. Review.

PMID:
7785505
18.

Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.

Wender PA, Staveness D.

Org Lett. 2014 Oct 3;16(19):5140-3. doi: 10.1021/ol502492b. Epub 2014 Sep 19.

19.

Supplemental Content

Support Center